Black Diamond Therapeutics (BDTX)
(Delayed Data from NSDQ)
$2.85 USD
-0.02 (-0.70%)
Updated Aug 28, 2025 04:00 PM ET
After-Market: $2.85 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth C Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BDTX 2.85 -0.02(-0.70%)
Will BDTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BDTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BDTX
Black Diamond (BDTX) Upgraded to Strong Buy: Here's Why
Are Medical Stocks Lagging Black Diamond Therapeutics (BDTX) This Year?
BDTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Black Diamond (BDTX) Upgraded to Buy: Here's What You Should Know
Other News for BDTX
BDTX forms NR7 on August 27
BDTX rises 1.05% on August 26, leaving the technical picture intact
Black Diamond Therapeutics: A Potential First-Line In NSCLC Trading At Cash
BDTX forms Stochastic Reached Overbought on August 25
Is BDTX building bullish momentum? MACD Bullish Centerline Cross shows up after surging 7.75%